402 related articles for article (PubMed ID: 1415199)
1. The uremic dyslipidemia: a cross-sectional and longitudinal study.
Avram MM; Goldwasser P; Burrell DE; Antignani A; Fein PA; Mittman N
Am J Kidney Dis; 1992 Oct; 20(4):324-35. PubMed ID: 1415199
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Burrell D; Antignani A; Fein PA; Goldwasser P; Mittman N; Avram MM
ASAIO Trans; 1990; 36(3):M331-5. PubMed ID: 2123635
[TBL] [Abstract][Full Text] [Related]
3. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis.
Siamopoulos KC; Elisaf MS; Bairaktari HT; Pappas MB; Sferopoulos GD; Nikolakakis NG
Perit Dial Int; 1995; 15(8):342-7. PubMed ID: 8785232
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
[TBL] [Abstract][Full Text] [Related]
5. The impact of CAPD treatment on lipid metabolism and cardiovascular risk.
Tan D; Fein PA; Antignani A; Mittman N; Avram MM
Adv Perit Dial; 1990; 6():233-7. PubMed ID: 1982815
[TBL] [Abstract][Full Text] [Related]
6. Fall of cholesterol with time on dialysis: impact on atherogenicity.
Lapuz M; Avram MM; Lustig A; Goldwasser P; Antignani A; Fein PA; Mittman N
ASAIO Trans; 1989; 35(3):258-60. PubMed ID: 2597459
[TBL] [Abstract][Full Text] [Related]
7. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
8. Lipid abnormalities in black renal patients.
Burrell DE; Antignani A; Goldwasser P; Mittman N; Fein PA; Slater PA; Gan A; Avram MM
N Y State J Med; 1991 May; 91(5):192-6. PubMed ID: 1857570
[TBL] [Abstract][Full Text] [Related]
9. Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis.
Yang X; Wang H; Zhu Z; Deng A
J Tongji Med Univ; 1997; 17(2):126-8. PubMed ID: 9639806
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease.
Kim SB; Yang WS; Kang ES; Min WK; Park JS
Perit Dial Int; 1997; 17(3):236-42. PubMed ID: 9237283
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Fytili CI; Progia EG; Panagoutsos SA; Thodis ED; Passadakis PS; Sombolos KI; Vargemezis VA
Ren Fail; 2002 Sep; 24(5):623-30. PubMed ID: 12380908
[TBL] [Abstract][Full Text] [Related]
13. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.
Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B
Nephron; 1996; 72(2):135-44. PubMed ID: 8684516
[TBL] [Abstract][Full Text] [Related]
14. Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis.
Steele J; Billington T; Janus E; Moran J
Atherosclerosis; 1989 Sep; 79(1):47-50. PubMed ID: 2803346
[TBL] [Abstract][Full Text] [Related]
15. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
Kimak E; Solski J; Janicka L; Ksaziek A; Janicki K
Clin Chem Lab Med; 2000 May; 38(5):421-5. PubMed ID: 10952225
[TBL] [Abstract][Full Text] [Related]
16. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
Saltissi D; Morgan C; Rigby RJ; Westhuyzen J
Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368
[TBL] [Abstract][Full Text] [Related]
18. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis.
Yiğitoğlu MR; Polat MF; Akçay F; Ari Z; Uyanik BS; Ozilgili HM
Jpn Heart J; 1997 Jan; 38(1):83-9. PubMed ID: 9186284
[TBL] [Abstract][Full Text] [Related]
19. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Navarro JF; Mora C; Muros M; García-Idoate G
Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
[TBL] [Abstract][Full Text] [Related]
20. Variability of peritoneal clearances for apolipoprotein and its relationship to susceptibility for atherosclerotic changes in CAPD.
Fein PA; Fletcher D; Antignani A; Goldwasser P; Jorden A; Lustig A; Avram MM
Adv Perit Dial; 1989; 5():185-90. PubMed ID: 2577408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]